Emerging psychoactive substance use among regular ecstasy users in Australia

Drug and Alcohol Dependence

Volumn 124, Issue 1-2, 2012, Pages 19-25

  Bruno, Raimondo ^a   Matthews, Allison J ^a   Dunn, Matthew ^b   Alati, Rosa ^c   McIlwraith, Fairlie ^c   Hickey, Sophie ^c   Burns, Lucy ^d   Sindicich, Natasha ^d  

^a UNIVERSITY OF TASMANIA   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

3,4 Methylenedioxymethamphetamine (MDMA); 4 Methylmethcathinone; Ecstasy; Emerging psychoactive substances; Mephedrone; Research chemical

Indexed keywords

1 BENZYLPIPERAZINE DERIVATIVE; 2,5 DIMETHOXY 4 ETHYLPHENETHYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4' METHYLMETHCATHINONE; 5 METHOXY N,N DIMETHYLTRYPTAMINE; BENZYLPIPERAZINE; BROLAMFETAMINE; CANNABIS; EMERGING PSYCHOACTIVE SUBSTANCE; KETAMINE; MESCALINE; METHYLENEDIOXYPYROVALERONE; N,N DIMETHYLTRYPTAMINE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CONSUMER; CRIMINAL BEHAVIOR; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG ABUSE PATTERN; DRUG DEPENDENCE; EMERGING PSYCHOACTIVE SUBSTANCE USE; FEMALE; HIGH RISK BEHAVIOR; HUMAN; INHALANT ABUSE; LEGAL ASPECT; LEGAL PROBLEM; MALE; MENTAL DISEASE; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; SOCIAL PROBLEM; SUBSTANCE ABUSE; TREND STUDY;

ADOLESCENT; ADULT; AUSTRALIA; DRUG USERS; FEMALE; HUMANS; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

CANNABIS;

EID: 84861845470     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.11.020     Document Type: Article

References (42)

1. Australian Crime Commission Illicit Drug Data Report 2008-09 2010, Commonwealth of Australia, Canberra, Available from: www.crimecommission.gov.au/publications/illicit-drug-data-report/illicit-drug-data-report-2009-10 (last accessed 04.11.11).
2. Australian Institute of Health and Welfare 2010 National Drug Strategy Household Survey 2011, AIHW, Canberra, Available from: www.aihw.gov.au/publication-detail/?id=32212254712 (last accessed 04.11.11).
3. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 2010, [epub ahead of print, doi:10.1177/0269881110378370].
4. Dargan P.I., Wood D.M. Techincal Report on Mephedrone. European Monitoring Centre for Drugs and Drug Addiction, London 2010, Available from: www.ofdt.fr/BDD/publications/docs/rarOEDTmephAnn1.pdf (last accessed 04.11.11).
5. Drug Enforcement Agency DEA Announces Arrests of Website Operators Selling Illegal Designer Drugs 2004, www.webcitation.org/5zv6KPjNO (last accessed 04.11.11).
6. Degenhardt L., Bruno R., Topp L. Is ecstasy a drug of dependence?. Drug Alcohol Depend. 2010, 107:1-10.
7. Department of Health and Ageing Prohibited Imports and Exports (Drugs and Precursor Chemicals) 2010, Available at: www.health.gov.au/internet/main/publishing.nsf/Content/4FC241CC1F06369CCA25744E001A0AA2/$File/substance%20list-dec10.pdf (last accessed 04.11.11).
8. Drees J.C., Stone J.A., Wu A.H. Morbidity involving the hallucinogenic designer amines MDA and 2C-I. J. Forensic Sci. 2009, 54:1485-1487.
9. Dunn M., Degenhardt L., Bruno R. Transition to and from injecting drug use among regular ecstasy users. Addict. Behav. 2010, 35:909-912.
10. European Monitoring Centre for Drugs and Drug Addiction Guidelines for the Risk Assessment of New Synthetic Drugs 1999, Office for Official Publications of the European Communities, Luxenbourg, Available at: www.emcdda.europa.eu/html.cfm/index33361EN.html (last accessed 04.11.11).
11. European Monitoring Centre for Drugs and Drug Addiction Report on the Risk Assessment of 2C-I, 2C-T-2 and 2C-T-7 in the Framework of the Joint Action on New Synthetic Drugs 2004, European Monitoring Centre for Drugs and Drug Addiction, Belgium, Available at: www.emcdda.europa.eu/html.cfm/index33353EN.html (last accessed 04.11.11).
12. European Monitoring Centre for Drugs and Drug Addiction 2010 Annual Report on the State of the Drugs Problem in Europe 2010, Publications Office of the European Union, Luxembourg, Available at: www.emcdda.europa.eu/publications/annual-report/2010 (last accessed 04.11.11).
13. GetHiigh.com.au, 2010. Recommended Legal Highs for the Big Day Out. Available at: (last accessed 04.11.11). http://www.webcitation.org/5zkMjM2mi.
14. Hopper J.W., Su Z., Looby A.R., Ryan E.T., Penetar D.M., Palmer C.M., Lukas S.E. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: an ecological momentary assessment study. Drug Alcohol Depend. 2006, 85:221-235.
15. Huang H.H., Bai Y.M. Persistent psychosis after ingestion of a single tablet of '2C-B'. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:293-294.
16. James D., Adams R.D., Spears R., Cooper G., Lupton D.J., Thompson J.P., Thomas S.H. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg. Med. J. 2010, [epub ahead of print: doi:10.1136/emj.2010.096636].
17. Lea T., Reynolds R., De Wit J. Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug Alcohol Rev. 2011, 30:438-440.
18. Matthews A., Bruno R. Tasmanian Trends in Ecstasy and Related Drug Markets 2009: Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2010, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Available at: ndarc.med.unsw.edu.au (last accessed 04.09.11).
19. McGlothlin W.H., Arnold D.O. LSD Revisited: a ten-year follow-up of medical LSD use. Arch. Gen. Psychiatry 1971, 24:35-49.
20. McKetin R. Methamphetamine precursor regulation: are we controlling or diverting the drug problem?. Addiction 2008, 103:521-523.
21. Parrott A.C. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004, 50:329-335.
22. Peters G.J., Kok G., Abraham C. Social cognitive determinants of ecstasy use to target in evidence-based interventions: a meta-analytical review. Addiction 2008, 103:109-118.
23. Ramo D.E., Grov C., Delucchi L., Kelly B.C., Parsons J.T. Typology of club drug use among young adults recruited using time-space sampling. Drug Alcohol Depend. 2010, 107:119-127.
24. Sherlock K., Conner M. Patterns of ecstasy use amongst club-goers on the UK 'dance scene'. Int. J. Drug Policy 1999, 10:117-129.
25. Shimizu E., Watanabe H., Kojima T., Hagiwara H., Fujisaki M., Miyatake R., Hashimoto K., Iyo M. Combined intoxication with methylone and 5-MeO-MIPT. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:288-291.
26. Stafford J., Burns L. Australian Trends in Ecstasy and Related Drug Markets 2010: Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2011, National Drug and Alcohol Research Centre, University of New South Wales, Available at: ndarc.med.unsw.edu. au (last accessed 04.09.11).
27. Topp L., Barker B., Degenhardt L. The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend. 2004, 73:33-40.
28. Topp L., Breen C., Kaye S., Darke S. Adapting the illicit drug reporting system (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'. Drug Alcohol Depend. 2004, 73:189-197.
29. Vardakou I., Pistos C., Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol. Lett. 2010, 197:157-162.
30. White B., Degenhardt L., Breen C., Bruno R., Newman J., Proudfoot P. Risk and benefit perceptions of party drug use. Addict. Behav. 2006, 31:137-142.
31. Wilkins C., Sweetsur P. Trends in population drug use in New Zealand: findings from national household surveying of drug use in 1998, 2001, 2003, and 2006. N. Z. Med. J. 2008, 121:61-71.
32. Wilkins C., Sweetsur P., Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev. 2008, 27:633-639.
33. Williams A. MPTP parkinsonism. Br. Med. J. (Clin. Res. Ed.) 1984, 289:1401-1402.
34. Winstock A., Marsden J. Mephedrone: Assessment of Health Risks and Harms 2010, European Monitoring Centre for Drugs and Drug Addiction, London, Available at: www.ofdt.fr/BDD/publications/docs/rarOEDTmephAnn1.pdf (last accessed 04.11.11).
35. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376. 1537-1537.
36. Winstock A.R., Marsden J., Mitcheson L. What should be done about mephedrone?. BMJ 2010, 340:c1605.
37. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
38. Winstock A.R., Ramsey J.D. Legal highs and the challenges for policy makers. Addiction 2010, 105:1685-1687.
39. Wood D.M., Dargan P.I. Mephedrone: a novel synthetic cathinone - a case series of sympathomimetic toxicity associated with its use. Clin. Toxicol. 2010, 48:290.
40. Wu L.T., Parrott A.C., Ringwalt C.L., Yang C., Blazer D.G. The variety of ecstasy/MDMA users: results from the national epidemiologic survey on alcohol and related conditions. Am. J. Addict. 2009, 18:452-461.
41. Wu L.T., Ringwalt C.L., Mannelli P., Patkar A.A. Hallucinogen use disorders among adult users of MDMA and other hallucinogens. Am. J. Addict. 2008, 17:354-363.
42. Wu L.T., Ringwalt C.L., Weiss R.D., Blazer D.G. Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use. Drug Alcohol Depend. 2009, 104:156-166.